Mental Health DailyResearch. Evidence. Perspective.Published research on lisdexamfetamine.
New Brazilian Psychiatric Association guidelines put cognitive behavioral therapy (CBT) first for bulimia and binge-eating disorder. When medication is needed, they recommend fluoxetine as a…
Read articleLisdexamfetamine remains the only FDA-approved medication for binge-eating disorder — a serious condition affecting roughly 1.2% of adults. A 2026 human laboratory study by McKee and colleag…
Read articleBinge-eating disorder (BED), characterized by recurrent episodes of overeating without compensatory behaviors, is a significant global health concern. Lisdexamfetamine dimesylate (LDX), the …
Read articleVyvanse (Lisdexamfetamine) is a prodrug comprised of the amino acid L-lysine coupled with dextroamphetamine, hence its chemical name “lis-dexamfetamine.” As a prodrug, Vyvanse is inactive un…
Read articleVyvanse (Lisdexamfetamine) is a psychostimulant medication manufactured by Shire Pharmaceuticals for the treatment of ADHD (attention-deficit/hyperactivity disorder). Many consider Vyvanse t…
Read articleVyvanse (Lisdexamfetamine) is a drug developed by Shire Pharmaceuticals as a successor to Adderall. Vyvanse was first approved for the treatment of attention-deficit/hyperactivity disorder (…
Read articleMethylphenidate is considered the first medication approved for the treatment of the condition known as “hyperactivity” in the 1960s. As attention-deficit/hyperactivity disorder gained more …
Read article
